Last reviewed · How we verify
Paroxetine CR for Major Depressive Episode — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Paroxetine CR for Major Depressive Episode (Paroxetine CR for Major Depressive Episode) — New York State Psychiatric Institute.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Paroxetine CR for Major Depressive Episode TARGET | Paroxetine CR for Major Depressive Episode | New York State Psychiatric Institute | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Paroxetine CR for Major Depressive Episode CI watch — RSS
- Paroxetine CR for Major Depressive Episode CI watch — Atom
- Paroxetine CR for Major Depressive Episode CI watch — JSON
- Paroxetine CR for Major Depressive Episode alone — RSS
Cite this brief
Drug Landscape (2026). Paroxetine CR for Major Depressive Episode — Competitive Intelligence Brief. https://druglandscape.com/ci/paroxetine-cr-for-major-depressive-episode. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab